These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 7769190)

  • 81. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
    Bermejo F; Aguas M; Chaparro M; Domènech E; Echarri A; García-Planella E; Guerra I; Gisbert JP; López-Sanromán A;
    Gastroenterol Hepatol; 2018 Mar; 41(3):205-221. PubMed ID: 29357999
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Inflammatory Bowel Disease - Non-biological treatment.
    Magro F; Cordeiro G; Dias AM; Estevinho MM
    Pharmacol Res; 2020 Oct; 160():105075. PubMed ID: 32653651
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients.
    Zelante A; Borgoni R; Galuppi C; Cifalà V; Melchiorri L; Gullini S; Baricordi O; Rizzo R
    Inflamm Bowel Dis; 2011 Aug; 17(8):E94-5. PubMed ID: 21604331
    [No Abstract]   [Full Text] [Related]  

  • 84. Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.
    Lennard-Jones JE
    Gut; 1983 Mar; 24(3):177-81. PubMed ID: 6337933
    [No Abstract]   [Full Text] [Related]  

  • 85. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 86. How effective are the usual treatments for Crohn's disease?
    Bebb JR; Scott BB
    Aliment Pharmacol Ther; 2004 Jul; 20(2):151-9. PubMed ID: 15233694
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Current medical treatment of inflammatory bowel disease].
    Bosques-Padilla F
    Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494
    [No Abstract]   [Full Text] [Related]  

  • 88. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.
    Faubion WA; Loftus EV; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Gastroenterology; 2001 Aug; 121(2):255-60. PubMed ID: 11487534
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.
    Kimura K; Yoshida A; Katagiri F; Takayanagi R; Yamada Y
    Biopharm Drug Dispos; 2019 Jul; 40(7):250-261. PubMed ID: 31256430
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study.
    Raknes G; Simonsen P; Småbrekke L
    J Crohns Colitis; 2018 May; 12(6):677-686. PubMed ID: 29385430
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Approach to steroid-dependent and steroid-refractory Crohn's disease.
    Lichtenstein GR
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S27-35. PubMed ID: 11685972
    [No Abstract]   [Full Text] [Related]  

  • 92. [Chronic inflammatory bowel diseases. Pathophysiology and drug therapy].
    von Ritter C
    Radiologe; 1998 Jan; 38(1):3-7. PubMed ID: 9530772
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use.
    Herrlinger KR; Noftz MK; Fellermann K; Schmidt K; Steinhoff J; Stange EF
    Aliment Pharmacol Ther; 2001 Mar; 15(3):363-9. PubMed ID: 11207511
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical perspectives in inflammatory bowel disease.
    Selby W
    Aust N Z J Med; 1996 Feb; 26(1):15-9. PubMed ID: 8775523
    [No Abstract]   [Full Text] [Related]  

  • 96. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.
    Fagan EA; Dyck RF; Maton PN; Hodgson HJ; Chadwick VS; Petrie A; Pepys MB
    Eur J Clin Invest; 1982 Aug; 12(4):351-9. PubMed ID: 6814926
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Maintenance therapy for inflammatory bowel disease.
    Feagan BG
    Am J Gastroenterol; 2003 Dec; 98(12 Suppl):S6-S17. PubMed ID: 14697913
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [New treatments for ulcerative colitis and Crohn's disease].
    Jewell DP
    Nihon Shokakibyo Gakkai Zasshi; 1989 Sep; 86(9):2323-62. PubMed ID: 2585802
    [No Abstract]   [Full Text] [Related]  

  • 99. Steroid use in Crohn's disease.
    Vavricka SR; Schoepfer AM; Scharl M; Rogler G
    Drugs; 2014 Mar; 74(3):313-24. PubMed ID: 24532122
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Update in medical therapy of ulcerative colitis: a practical approach.
    Katz S
    J Clin Gastroenterol; 2002 Apr; 34(4):397-407. PubMed ID: 11907350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.